WO2022216014A1 - 항-cntn4 항체 및 그의 용도 - Google Patents
항-cntn4 항체 및 그의 용도 Download PDFInfo
- Publication number
- WO2022216014A1 WO2022216014A1 PCT/KR2022/004890 KR2022004890W WO2022216014A1 WO 2022216014 A1 WO2022216014 A1 WO 2022216014A1 KR 2022004890 W KR2022004890 W KR 2022004890W WO 2022216014 A1 WO2022216014 A1 WO 2022216014A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- cntn4
- antigen
- seq
- binding fragment
- Prior art date
Links
- 230000027455 binding Effects 0.000 claims abstract description 173
- 238000009739 binding Methods 0.000 claims abstract description 173
- 108091007433 antigens Proteins 0.000 claims abstract description 170
- 102000036639 antigens Human genes 0.000 claims abstract description 170
- 239000000427 antigen Substances 0.000 claims abstract description 164
- 239000012634 fragment Substances 0.000 claims abstract description 146
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 64
- 201000011510 cancer Diseases 0.000 claims abstract description 52
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 89
- 101000909504 Homo sapiens Contactin-4 Proteins 0.000 claims description 68
- 102100024340 Contactin-4 Human genes 0.000 claims description 45
- 239000002246 antineoplastic agent Substances 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 31
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 21
- 102000054221 human CNTN4 Human genes 0.000 claims description 21
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 17
- 108020004707 nucleic acids Proteins 0.000 claims description 17
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 16
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 16
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 16
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 16
- 229940127089 cytotoxic agent Drugs 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 12
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 238000010494 dissociation reaction Methods 0.000 claims description 8
- 230000005593 dissociations Effects 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 7
- 239000013604 expression vector Substances 0.000 claims description 7
- 238000011319 anticancer therapy Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000001959 radiotherapy Methods 0.000 claims description 5
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 4
- 101000909511 Mus musculus Contactin-4 Proteins 0.000 claims description 4
- 238000003259 recombinant expression Methods 0.000 claims description 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 abstract description 4
- 230000021633 leukocyte mediated immunity Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 51
- 108090000623 proteins and genes Proteins 0.000 description 30
- 108020004414 DNA Proteins 0.000 description 25
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 20
- 241000287828 Gallus gallus Species 0.000 description 15
- 235000013330 chicken meat Nutrition 0.000 description 15
- 239000013598 vector Substances 0.000 description 15
- 238000002965 ELISA Methods 0.000 description 14
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 12
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000012790 confirmation Methods 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- 101100496557 Mus musculus Cntn4 gene Proteins 0.000 description 8
- 230000008929 regeneration Effects 0.000 description 8
- 238000011069 regeneration method Methods 0.000 description 8
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 206010062016 Immunosuppression Diseases 0.000 description 7
- 238000010828 elution Methods 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 230000001506 immunosuppresive effect Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 6
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 6
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 6
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 6
- 239000000611 antibody drug conjugate Substances 0.000 description 6
- 229940049595 antibody-drug conjugate Drugs 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 238000013207 serial dilution Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 108010074708 B7-H1 Antigen Proteins 0.000 description 4
- 102000008096 B7-H1 Antigen Human genes 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
- 229930012538 Paclitaxel Natural products 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 230000006044 T cell activation Effects 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 229950009791 durvalumab Drugs 0.000 description 4
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229960003301 nivolumab Drugs 0.000 description 4
- 229960001592 paclitaxel Drugs 0.000 description 4
- 229960002621 pembrolizumab Drugs 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 229960003852 atezolizumab Drugs 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229960005386 ipilimumab Drugs 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 229940127084 other anti-cancer agent Drugs 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 241000194035 Lactococcus lactis Species 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 101100235511 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) LHP1 gene Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 235000014897 Streptococcus lactis Nutrition 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 229940124650 anti-cancer therapies Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 229950002916 avelumab Drugs 0.000 description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 190000008236 carboplatin Chemical compound 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000011037 discontinuous sequential dilution Methods 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000008629 immune suppression Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 150000003057 platinum Chemical class 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 239000012146 running buffer Substances 0.000 description 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- 239000012275 CTLA-4 inhibitor Substances 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- -1 EGFR inhibitors Substances 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 229940102550 Estrogen receptor antagonist Drugs 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 108700012941 GNRH1 Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241000320412 Ogataea angusta Species 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 239000012271 PD-L1 inhibitor Substances 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 201000004283 Shwachman-Diamond syndrome Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046392 Ureteric cancer Diseases 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 201000003761 Vaginal carcinoma Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000001745 anti-biotin effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000003418 antiprogestin Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 201000001343 fallopian tube carcinoma Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000012917 library technology Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000012516 mab select resin Substances 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 208000011866 pituitary adenocarcinoma Diseases 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000003623 progesteronic effect Effects 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940066453 tecentriq Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000011294 ureter cancer Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 201000004916 vulva carcinoma Diseases 0.000 description 1
- 208000013013 vulvar carcinoma Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Definitions
- the present invention relates to anti-CNTN4 antibodies or antigen-binding fragments thereof, pharmaceutical compositions comprising them, and their use for activating T cells, such as for the treatment of cancer.
- the human body has a defense system that protects itself from external invaders (viruses, toxins, etc.) and harmful internal changes (cancer cell mutations).
- cancer cells Unlike normal cells, cancer cells have specific antigens on their surface and are destroyed by the immune system in the early stage of cancer development. Afterwards, when the balance between the cancer cells that want to proliferate indefinitely and the immune cells that try to attack them are out of balance, the cancer cells begin to multiply. As cancer cells grow further, the body's immune system is disturbed. At this time, some cancer cells use the immune checkpoint of immune cells to evade immunity. .
- Immune checkpoint inhibitors are drugs that attack cancer cells by activating T cells by blocking the activation of immune checkpoint proteins involved in T cell suppression, and include CTLA-4, PD-1, and PD-L1 inhibitors.
- Representative drugs currently on the market include ipilimumab (brand name: YERVOY®) as a CTLA-4 monoclonal antibody, nivolumab (brand name: OPDIVO®) as a PD-1 monoclonal antibody, pembrolizumab (brand name: KEYTRUDA®), etc.
- PD -L1 monoclonal antibody includes atezolizumab (trade name: TECENTRIQ®) and durvalumab (trade name: IMFINZI®).
- the present invention is to provide an antibody or antigen-binding fragment thereof that binds to the CNTN4 protein and neutralizes the immune evasion mechanism of CNTN4.
- the present invention also provides a composition for preventing or treating diseases caused by decreased T cell activity, such as cancer, by activating T cells by blocking the immune evasion mechanism of CNTN4 using the antibody or antigen-binding fragment thereof.
- the present invention also provides a composition for analysis or detection of CNTN4 protein using the antibody or antigen-binding fragment thereof.
- the present invention provides an anti-CNTN4 antibody or antigen-binding fragment thereof that specifically binds to the CNTN4 protein.
- the antibody or antigen-binding fragment specifically binds to a CNTN4 protein, such as a human or mouse CNTN4 protein, and neutralizes the immune evasion mechanism of CNTN4. Accordingly, the antibody or antigen-binding fragment of the present invention can increase the activity of T cells, such as CD4+ T cells or CD8+ T cells, that were inhibited by CNTN4.
- the present invention provides
- a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 70;
- a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:88;
- a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 116;
- a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 58;
- a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:89;
- a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 115;
- an anti-CNTN4 antibody or antigen-binding fragment thereof comprising a.
- the present invention provides
- heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 2
- an anti-CNTN4 antibody or antigen-binding fragment thereof comprising a.
- the present invention provides
- a light chain variable region comprising the amino acid sequence of SEQ ID NO: 156;
- heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 159
- an anti-CNTN4 antibody or antigen-binding fragment thereof comprising a.
- the antigen-binding fragment of the invention is a Fab, Fab', Fab'-SH, Fv, single chain antibody scFv, (Fab')2 fragment, single domain antibody, diabody (dAb), or linear antibody. It may be an antibody fragment selected from the group consisting of, and the antibody may be a chimeric antibody or a humanized antibody.
- the present invention provides a nucleic acid molecule encoding said antibody or antigen-binding fragment thereof and a recombinant expression vector comprising said nucleic acid molecule.
- the present invention also provides a composition for preventing or treating cancer, comprising the antibody or antigen-binding fragment thereof as an active ingredient.
- the pharmaceutical composition may be used in combination with additional anticancer agents, such as immune checkpoint inhibitors or chemotherapeutic agents, or may be used in combination with radiation therapy.
- the present invention also provides a composition for analyzing or detecting a CNTN4 protein, comprising the antibody or antigen-binding fragment thereof.
- the present invention provides the use of an anti-CNTN4 antibody or antigen-binding fragment thereof for the prevention or treatment of cancer.
- the present invention provides the use of an anti-CNTN4 antibody or antigen-binding fragment thereof for the manufacture of a medicament for the prophylaxis or treatment of cancer.
- the present invention provides a method of preventing or treating cancer comprising administering to a subject an effective amount of an anti-CNTN4 antibody or antigen-binding fragment thereof.
- the present invention provides an effective amount of an anti-CNTN4 antibody or antigen-binding fragment thereof; And it provides a method for preventing or treating cancer comprising administering to the subject an effective amount of an additional anticancer agent.
- an additional anticancer agent for example, an immune checkpoint inhibitor or a chemotherapeutic agent may be used.
- the novel anti-CNTN4 antibody or antigen-binding fragment thereof of the present invention activates T cells by blocking the immune evasion mechanism of CNTN4, and thus can be effectively used for the prevention or treatment of diseases, particularly cancer, caused by decreased T cell activity. Accordingly, when the anti-CNTN4 antibody of the present invention is used, an excellent anticancer effect can be exhibited against a cancer that could not achieve a therapeutic effect with the existing immunotherapy.
- 1 and 2 show the amino acid sequences of the light and heavy chain variable regions of scFv antibody fragments selected through a phage display library. Sequences indicated by solid and dashed lines indicate the CDR sequences of each region.
- Figure 3 shows the amino acid sequence of the variable region used to prepare the anti-CNTN4 humanized antibody.
- the present invention provides an anti-CNTN4 antibody or antigen-binding fragment thereof that specifically binds to the CNTN4 protein.
- an anti-CNTN4 antibody or antigen-binding fragment thereof of the invention comprises:
- a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 70;
- a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:88;
- a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 116;
- a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 58;
- a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:89;
- a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 115;
- Table 1 shows the CDR sequences of each light and heavy chain variable region for the anti-CNTN4 antibody or antigen-binding fragment thereof of the present invention.
- the anti-CNTN4 antibody or antigen-binding fragment thereof of the present invention may be one comprising a pair of each light chain variable region and heavy chain variable region mentioned in Tables 4 and 5.
- the antibody or antigen-binding fragment thereof of the present invention comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 1; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 2 (S1).
- the antibody or antigen-binding fragment thereof of the present invention comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:3; And it may include a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 2 (S2).
- Other antibodies or antigen-binding fragments thereof may also comprise two pairs of light and heavy chain variable regions in the same manner.
- the anti-CNTN4 antibody or antigen-binding fragment thereof of the present invention comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 18; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 2.
- the anti-CNTN4 antibody or antigen-binding fragment thereof of the present invention may be one comprising each pair of light chain variable regions and/or heavy chain variable regions mentioned in Table 12.
- the antibody or antigen-binding fragment thereof of the present invention comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 18; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 159 (LAH2).
- the antibody or antigen-binding fragment thereof of the present invention comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 156; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 159 (L1H2).
- the antibody or antigen-binding fragment thereof of the present invention comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 158; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 159 (L2H2).
- the anti-CNTN4 antibody or antigen-binding fragment thereof of the present invention comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 156; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 159.
- the light chain or heavy chain variable region includes a specific amino acid sequence, it means that it includes the entire amino acid sequence, has the entire amino acid sequence, or consists of the corresponding amino acid sequence.
- the antibody or antigen-binding fragment thereof comprises a light chain CDR1 having the amino acid sequence of SEQ ID NO: 70; a light chain CDR2 having the amino acid sequence of SEQ ID NO:88; a light chain CDR3 having the amino acid sequence of SEQ ID NO: 116; a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 58; a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 89; and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 115.
- the antibody or antigen-binding fragment thereof comprises a light chain CDR1 consisting essentially of the amino acid sequence of SEQ ID NO: 70; a light chain CDR2 consisting essentially of the amino acid sequence of SEQ ID NO:88; a light chain CDR3 consisting essentially of the amino acid sequence of SEQ ID NO: 116; a heavy chain CDR1 consisting essentially of the amino acid sequence of SEQ ID NO: 58; a heavy chain CDR2 consisting essentially of the amino acid sequence of SEQ ID NO:89; and a heavy chain CDR3 consisting essentially of the amino acid sequence of SEQ ID NO: 115.
- the antibody or antigen-binding fragment thereof comprises a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 70; light chain CDR2 consisting of the amino acid sequence of SEQ ID NO: 88; light chain CDR3 consisting of the amino acid sequence of SEQ ID NO: 116; heavy chain CDR1 consisting of the amino acid sequence of SEQ ID NO: 58; heavy chain CDR2 consisting of the amino acid sequence of SEQ ID NO: 89; and a heavy chain CDR3 consisting of the amino acid sequence of SEQ ID NO: 115.
- the antibody or antigen-binding fragment thereof comprises a light chain variable region having the amino acid sequence of SEQ ID NO: 18 and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 2, or a light chain having the amino acid sequence of SEQ ID NO: 156 a variable region and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 159.
- the antibody or antigen-binding fragment thereof comprises a light chain variable region consisting essentially of the amino acid sequence of SEQ ID NO: 18 and a heavy chain variable region consisting essentially of the amino acid sequence of SEQ ID NO: 2, or the amino acids of SEQ ID NO: 156 and a light chain variable region consisting essentially of the sequence and a heavy chain variable region consisting essentially of the amino acid sequence of SEQ ID NO: 159.
- the antibody or antigen-binding fragment thereof comprises a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 18 and a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 2, or a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 156 region and a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 159.
- an antibody or antigen-binding fragment thereof comprising an enumerated amino acid sequence may comprise, whether essential or not, an additional unlisted amino acid sequence.
- an antibody or antigen-binding fragment thereof consisting essentially of the enumerated amino acid sequences may comprise substitutions of one or more amino acid residues that do not substantially affect the properties of the antibody or fragment thereof.
- CDR complementarity determining region
- the antibody or antigen-binding fragment thereof of the present invention may comprise a sequence in which the framework region of the scFv is fully or partially humanized.
- a partially humanized sequence it may be at least about 60%, at least about 70%, at least about 80% humanized compared to a fully humanized sequence, and some of the fully humanized sequences (eg, 1, 2, 3). dog, 4 or 5, etc.) may be back mutated.
- the antibody or antigen-binding fragment thereof comprising the humanized sequence may have the same or substantially no significant difference in binding ability to CNTN-4 even when compared to a non-humanized antibody or antigen-binding fragment thereof.
- the term “antibody” refers to an immune system capable of specifically binding to a target, e.g., carbohydrate, polynucleotide, lipid, polypeptide, protein, etc., via at least one antigen recognition site located in the variable region of an immunoglobulin molecule. It is a globulin molecule.
- the term “antibody” herein refers to an intact polyclonal or monoclonal antibody, as well as an antigen binding fragment thereof, an antibody fragment, a fusion protein comprising any other modified arrangement of an immunoglobulin molecule comprising an antigen recognition site.
- immunoglobulin (Ig)M immunoglobulin (Ig)M, IgD, IgG, IgA, and IgE, each of which contains heavy chains made from heavy chain constant region genes ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ .
- the light and heavy chains of an antibody are divided into a variable region having a different amino acid sequence and a constant region having the same amino acid sequence for each antibody, and the heavy chain constant regions include CH1, H (hinge), CH2, CH3 domains. This exists Each domain consists of two ⁇ -sheets, and an intramolecular disulfide bond is connected between them.
- A-01 an antibody comprising a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 2 is referred to as "A-01".
- L1H2 an antibody comprising a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 159.
- An antibody of the invention may be a chimeric antibody, a humanized antibody, or a human antibody.
- chimeric antibody refers to an antibody in which the variable region sequences are from one species and the constant region sequences are from another species, e.g., the variable region sequences are from a mouse or chicken antibody, and the constant region
- the sequence refers to an antibody derived from a human antibody.
- humanized antibody refers to an antibody in which CDR sequences derived from the germline of another mammalian species, for example, mouse or chicken, have been inserted into human framework sequences.
- the framework sequence may be further modified, for example, through back mutation.
- human antibody refers to an antibody comprising variable regions in which both the framework and CDR regions are derived from human immunoglobulin sequences.
- the constant regions of antibodies are also derived from human immunoglobulin sequences.
- antibody fragment refers to antigen-binding fragments that typically comprise at least a portion of the antigen-binding or variable region (eg, one or more CDRs) of a parent antibody and analogs of an antibody. it means. Antibody fragments retain at least some of the binding specificity of the parent antibody. Examples of antibody fragments that may be used herein are Fab, Fab', Fab'-SH, Fv, single chain antibody scFv, (Fab')2 fragment, single domain antibody, diabody (dAb), or linear antibody, It is not limited.
- a Fab fragment refers to a monovalent fragment consisting of the VL, VH, CL and CH1 domains.
- Fab' fragments differ from Fab fragments in that a few residues are added at the carboxy terminus of the CH1 domain, including one or more cysteines from the antibody hinge region.
- Fab'-SH refers to Fab' in which the cysteine residues of the constant domain bear a free thiol group.
- F(ab')2 antibody fragments are produced as pairs of Fab' fragments via hinge cysteines between the Fab' fragments.
- Fv is the smallest antibody fragment containing a complete antigen recognition site and antigen binding site. This fragment consists of a dimer in which one heavy chain variable region and one light chain variable region are tightly non-covalently associated. These two regions fold to form six hypervariable loops (3 loops each from the heavy and light chains), which provide amino acid residues for antigen binding and confer antigen binding specificity to the antibody. However, even a single variable region has the ability to recognize and bind antigen, although with a lower affinity than the entire binding site.
- Single chain antibody scFvs are antibody fragments comprising VH and VL antibody domains linked by a single polypeptide chain.
- the scFv polypeptide further comprises a polypeptide linker between the VH and VL domains which enables the scFv to form the desired structure for antigen binding.
- scFv antibody fragment antigen binding fragment scFv, scFv antibody, antibody scFv, or simply scFv.
- Diabodies consist of a short linker (approximately 5-10) between the VH and VL domains such that intrachain, but not interchain, pairing of the V domain is achieved to produce a bivalent fragment, i.e., a fragment with two antigen binding sites. dog residues) to construct an scFv fragment.
- Bispecific diabodies are heterodimers consisting of two “bridged” scFv fragments in which the VH and VL domains of the two antibodies are in different polypeptide chains.
- the anti-CNTN4 antibody or antigen-binding fragment thereof of the present invention may specifically bind to a CNTN4 protein, preferably a human or mouse CNTN4 protein.
- the term “specifically binds to” or “specific for” refers to being deterministic for the presence of a target in the presence of a heterogeneous population of molecules, including biological molecules Refers to measurable and reproducible interactions such as binding between antibodies.
- a specific target eg, an epitope
- an antibody that specifically binds to a specific target binds to that target with greater affinity, greater avidity, more readily, and/or with a longer duration than it binds another target. means an antibody that
- the term "specifically binding to human CNTN4 protein” refers to an antibody that binds to human CNTN4 protein with a dissociation constant (Kd) of 5 ⁇ 10 -7 M or less, preferably 1 ⁇ 10 -7 M or less. can do. Accordingly, the anti-CNTN4 antibody or antigen-binding fragment thereof of the present invention may bind to human CNTN4 protein with a dissociation constant (Kd) of 5 X 10 -7 M or less, preferably, with a Kd of 1 ⁇ 10 -7 M or less. have.
- Kd refers to the equilibrium dissociation constant of a particular antibody-antigen interaction, said constant having units of M.
- the Kd value for an antibody can be determined using methods well established in the art.
- a preferred method for measuring the Kd value of an antibody is a method using surface plasmon resonance (SRP), preferably a biosensor system such as a Biacore® system.
- SRP surface plasmon resonance
- an anti-CNTN4 antibody or antigen-binding fragment thereof of the invention is monospecific and specifically binds to a single epitope, ie, the CNTN4 protein.
- the anti-CNTN4 antibody or antigen-binding fragment thereof of the invention is a multispecific, such as a bispecific or trispecific antibody molecule.
- a multispecific antibody molecule comprises a plurality of variable regions, each variable region having binding specificity for a different epitope.
- the first variable region of the bispecific antibody molecule has a first binding specificity for a first epitope, e.g., a CNTN4 protein
- the second variable region is a target protein other than a second epitope, e.g., a CNTN4 protein.
- has a second binding specificity for eg, including but not limited to, CTLA-4, PD-1 or PD-L1).
- the bispecific antibody molecule is CNTN4; and specifically binds to any one of CTLA-4, PD-1 or PD-L1.
- any combination of said molecules comprises a multispecific antibody molecule, e.g., a first binding specificity for CNTN4, and a second binding specificity for two or more of CTLA-4, PD-1 or PD-L1. and a trispecific antibody comprising a third binding specificity.
- Multispecific antibody molecules of the invention can be constructed using standard molecular biological techniques known to those of skill in the art (eg, recombinant DNA and protein expression technology).
- an anti-CNTN4 antibody or antigen-binding fragment thereof of the invention is capable of forming an antibody-drug conjugate (ADC).
- ADC antibody-drug conjugate
- M an antibody molecule
- L an optional linker or linker unit
- D a suitable drug or prodrug
- n an integer from about 1 to about 20.
- the drug included in the ADC may be appropriately selected according to therapeutic or diagnostic use, etc. as long as it does not interfere with the specific binding of the antibody of the present invention.
- the drug includes, but is not limited to, a cytotoxic agent (eg, a chemotherapeutic agent), a prodrug converting enzyme, a radioactive isotope or compound, or a toxin.
- a cytotoxic agent eg, a chemotherapeutic agent
- a prodrug converting enzyme e.g., a radioactive isotope or compound
- a toxin e.g., a cytotoxic agent, eg, a chemotherapeutic agent
- Drugs and linkers that may be included in the ADC and methods for preparing the same may be according to methods known in the art.
- the anti-CNTN4 antibody or antigen-binding fragment thereof of the present invention contains 5 nM or less, preferably 3 nM or less, more preferably 2 nM or even more preferably 1 nM or less as measured by ELISA assay. Binds to CNTN4 protein (eg human or mouse CNTN4 protein) with an EC50.
- CNTN4 protein eg human or mouse CNTN4 protein
- EC50 is a term related to in vitro or in vivo assays using antibodies, and refers to the concentration of antibody that induces 50% of the maximal response, i.e., a response intermediate between the maximal response and the baseline (baseline). do.
- Another aspect of the invention relates to a nucleic acid molecule encoding an anti-CNTN4 antibody or antigen-binding fragment thereof of the invention.
- the nucleic acid may be present in whole cells or in cell lysates, or may be specifically present in purified or substantially pure form. Nucleic acids can be separated from other cellular components or other contaminants such as other cellular nucleic acids or proteins by standard techniques such as alkaline/SDS treatment, CsCl banding, column chromatography, agarose gel electrophoresis and other sugars. An "isolated” or “substantially pure isolated” nucleic acid when purified and removed by methods well known in the art.
- a nucleic acid of the invention may be, for example, DNA or RNA, and may or may not contain intron sequences.
- the nucleic acid is a cDNA molecule.
- the nucleic acid molecule of the invention encodes a light chain region, a heavy chain region, or both light and heavy chain regions of an anti-CNTN4 antibody or antigen-binding fragment thereof of the invention, preferably a light chain variable region, a heavy chain variable region, or both light and heavy chain variable regions.
- the nucleic acid molecule of the invention encodes a light chain variable region comprising the amino acid sequence of SEQ ID NO: 18 or SEQ ID NO: 156, or encodes a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 159 .
- a nucleic acid molecule of the invention encodes antibody A-01 or antibody L1H2.
- DNA fragments encoding the VL and/or VH regions can be further manipulated, for example, by standard recombinant DNA techniques, resulting in the variable region genes being converted to full-length antibody chain genes, Fab fragments. gene or scFv gene.
- the VL- or VH-encoding DNA fragment is operable on other proteins, such as antibody constant regions, such as the hIgG1 Fc region (hFc) or hC ⁇ region, or other DNA fragments encoding flexible linkers.
- the term "operably linked" means when two DNA fragments are joined such that the amino acid sequence encoded by the two DNA fragments remains in-frame. .
- the isolated DNA encoding the VH region can be converted to a full-length heavy chain gene by operably linking the VH-encoding DNA to other DNA molecules encoding heavy chain constant regions (CH1, CH2 and CH3).
- the heavy chain constant region may be an IgG1, IgG2, IgG3, IgG4, IgA, IgE, IgM or IgD constant region.
- the VH-encoding DNA may be operably linked to another DNA molecule encoding only the heavy chain CH1 constant region.
- VL- and VH-encoding DNA fragments can be operably linked to a flexible linker such as other fragments encoding the amino acid sequence (Gly4-Ser)3, resulting in VL and
- the VH sequence can be expressed as a continuous single-chain protein with VL and VH regions joined by a flexible linker.
- Nucleic acid sequences of the invention can be isolated from a variety of sources, genetically engineered, amplified and/or recombinantly expressed. Any recombinant expression system can be used, including insect or mammalian systems, in addition to bacteria such as yeast. For example, nucleic acid manipulations such as subcloning into expression vectors, labeling probes, sequencing and hybridization can be performed as known in the art.
- the present invention provides a recombinant expression vector comprising the nucleic acid molecule.
- vector refers to a DNA molecule capable of self-replication in prokaryotic and/or eukaryotic cells, used interchangeably with recombinant vectors, cloning vectors, and expression vectors, which generally refers to the transfer of a gene or DNA fragment into a cell. It is used as an intermediate carrier for delivery to, etc.
- a vector is usually an origin of replication capable of replication in prokaryotic and/or eukaryotic cells, a selectable marker gene capable of conferring resistance to specific conditions/substances such as antibiotic-degrading enzymes, a promoter capable of transcription of the gene in eukaryotic or prokaryotic cells, Translatable sequences include, but are not limited to.
- vector refers to a circular double standard DNA loop into which additional DNA fragments can be spliced.
- viral vector in which additional DNA fragments can be spliced into the viral genome.
- Certain vectors are capable of autonomous replication in the host cell into which they are introduced (eg, bacterial vectors having a bacterial origin of replication and episomal mammalian vectors).
- the present invention also provides a host cell comprising the vector.
- Host cells include, but are not limited to, cells of mammalian, plant, insect, fungal or bacterial origin.
- Bacterial cells include Gram-positive bacteria or Gram-negative bacteria, such as cells from several species of the genus Escherichia, such as E. coli and Pseudomonas.
- yeast cells can be used.
- Expression in yeast can use yeast strains such as, inter alia, Pichia pastoris, Saccharomyces cerevisiae and Hansenulapolymorpha.
- insect cells such as cells derived from Drosophila and Sf9, can be used as host cells.
- mammalian cells such as Chinese Hamster Ovary (CHO) cells, Simian COS cells, BHK cells, NSO cells or Bowes melanoma cells
- mammalian cells such as Chinese Hamster Ovary (CHO) cells, Simian COS cells, BHK cells, NSO cells or Bowes melanoma cells
- the host cells in this case may be human cells, such as HeLa, 911, AT1080, A549, 293 and HEK293 cells.
- the antibody or antigen-binding fragment thereof of the present invention can be prepared according to a conventionally known method.
- an antibody such as a monoclonal antibody, of the invention expresses an antibody having the desired sequence or functional properties after injection of a CNTN4 antigen into a test subject (eg, a mouse) according to methods known in the art. It can be prepared by isolating the hybridoma.
- DNA encoding the monoclonal antibody is immediately isolated using conventional methods (eg, by using oligonucleotide probes capable of binding specifically to genes encoding the heavy and light chains of the monoclonal antibody) and are sequenced Hybridoma cells serve as a preferred source of such DNA.
- the DNA is placed into an expression vector and then transfected into host cells such as E. coli cells, Simian COS cells, CHO cells, or myeloma cells that do not otherwise produce immunoglobulin proteins to host a recombinant host. Synthesis of monoclonal antibodies in cells can be obtained.
- an antibody or antigen-binding fragment thereof of the invention can be prepared using antibody display technology, such as phage library technology.
- the antibody phage library is cloned in the form of fusion of the phage surface protein (pIII) in the phagemid vector in the heavy and light chain variable region genes of the human antibody, expressed in E. coli, and then infected with M13 helper phage, and the phage Prepare an antibody library in which antibody fragments (scFv or Fab) having various combinations of sequences of heavy and light chain variable regions are displayed on the surface of . From this library, a fragment of an antibody that binds to a specific antigen is isolated from this library using the panning method, and the characteristics of the isolated antibody fragment are identified, then converted into a whole IgG form and expressed in large quantities in animal cells to express a specific human monoclonal antibody. Produces raw antibodies
- phagemid vector is a plasmid DNA having a phage origin of replication, and typically has an antibiotic resistance gene as a selection marker.
- the gIII gene or a part thereof of M13 phage is included, and the ScFv gene is ligated to the 5' end of the gIII gene and expressed through a transformant.
- helper phage is a phage that provides the necessary genetic information for the phagemid to assemble into phage particles. Since gIII or only a part of the phage gene exists in the phagemid, the host cell (transformant) transformed with the phagemid is infected with a helper phage to supply the remaining phage genes. There are types such as M13K07 or VCSM13, and most transformants infected with helper phage including antibiotic resistance genes such as kanamycin can be selected. In addition, since there is a defect in the packaging signal, the phagemid gene is selectively assembled into the phage particle rather than the helper phage gene.
- the antibody or antigen-binding fragment thereof of the present invention restores an immune response suppressed by binding of the CNTN4 protein. It has been found that CNTN4 protein inhibits proliferation of T cells, particularly CD4+ T cells and CD8+ T cells.
- the antibody or antigen-binding fragment thereof of the present invention increases T cell activity, particularly, CD4+ T cell or CD8+ T cell activity by specifically binding to CNTN4 protein, and thus can be used to treat diseases related to immune suppression.
- the antibody or antigen-binding fragment thereof of the invention increases T cell activity. Accordingly, the antibody or antigen-binding fragment thereof of the present invention may activate T cells, in particular, CD4+ T cells or CD8+ T cells. In one embodiment, the antibody or antigen-binding fragment thereof of the present invention may increase the proliferation of T cells that have been inhibited by CNTN4. The antibody or antigen-binding fragment thereof of the present invention has excellent CNTN4 neutralizing ability.
- the present invention relates to induction of T cell activation using an anti-CNTN4 antibody or antigen-binding fragment thereof.
- the present invention provides a method of inducing or enhancing T cell activation comprising administering to a subject an effective amount of an anti-CNTN4 antibody or antigen-binding fragment thereof.
- the present invention provides the use of an anti-CNTN4 antibody or antigen binding fragment thereof for inducing or enhancing T cell activation.
- the present invention provides a pharmaceutical composition for inducing or enhancing T cell activation, comprising an anti-CNTN4 antibody or antigen-binding fragment thereof.
- the present invention relates to the prevention, improvement or treatment of diseases related to immunosuppression using an anti-CNTN4 antibody or antigen-binding fragment thereof.
- the present invention provides a method of preventing, ameliorating or treating an immune suppression-related disease, comprising administering to a subject an effective amount of an anti-CNTN4 antibody or antigen-binding fragment thereof.
- the present invention provides the use of an anti-CNTN4 antibody or antigen-binding fragment thereof for the prevention, amelioration or treatment of a disease associated with immunosuppression.
- the present invention provides a pharmaceutical composition for preventing, ameliorating or treating a disease related to immunosuppression, comprising an anti-CNTN4 antibody or antigen-binding fragment thereof.
- subject means a human and non-human animals.
- Non-human animals include all vertebrates, including mammals and non-mammals, including non-human primates, sheep, dogs, cats, cattle, horses, chickens, amphibians and reptiles, for example
- mammals such as non-human primates, sheep, dogs, cats, cattle and horses are preferred.
- a preferred subject is a human in need of activation or enhancement of an immune response.
- the anti-CNTN4 antibody or antigen-binding fragment thereof of the present invention can activate T cells by blocking the binding of CNTN4 protein and/or enhance an immune response against cancer cells in a cancer patient, so that cancer cells in vivo By inhibiting the growth of cells, it can be usefully used to prevent, improve or treat cancer.
- the present invention provides the use of an anti-CNTN4 antibody or antigen-binding fragment thereof for the prevention or treatment of cancer.
- the present invention provides the use of an anti-CNTN4 antibody or antigen-binding fragment thereof for the manufacture of a medicament for the prophylaxis or treatment of cancer.
- the present invention provides a method of preventing or treating cancer comprising administering to a subject an effective amount of an anti-CNTN4 antibody or antigen-binding fragment thereof.
- the present invention provides an effective amount of an anti-CNTN4 antibody or antigen-binding fragment thereof; And it provides a method for preventing or treating cancer comprising administering to the subject an effective amount of an additional anticancer agent.
- the additional anticancer agent may be an immune checkpoint inhibitor or a chemotherapeutic agent, and the immune checkpoint inhibitor may be one or more selected from the group consisting of an anti-CTLA-4 antibody, an anti-PD-1 antibody, and an anti-PD-L1 antibody. .
- said effective amount of an anti-CNTN4 antibody or antigen-binding fragment thereof; and the effective amount of the additional anticancer agent may be administered to the subject simultaneously as one agent, or may be administered to the subject simultaneously or sequentially as separate agents.
- cancers for which growth can be inhibited when the antibody of the present invention is used include cancers that normally respond to immunotherapy.
- cancers of the invention include melanoma (eg, metastatic malignant melanoma), kidney cancer (eg, clear cell carcinoma), prostate cancer (eg, hormone refractory prostate adenocarcinoma), breast cancer, colon cancer, rectal cancer, colon cancer and lung cancer (eg, non-small cell lung cancer).
- the treatment target of the present invention includes refractory or recurrent malignant tumors whose growth can be inhibited when the antibody of the present invention is used.
- Examples of other cancers that can be treated using the methods of the present invention include bone cancer, pancreatic cancer, skin cancer, head or neck cancer, skin and intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, anal cancer, stomach cancer, testicular cancer , cervical cancer, fallopian tube carcinoma, endometrial carcinoma, cervical carcinoma, vaginal carcinoma, female vulvar carcinoma, Hodgkin's disease, non-Hodgkin's lymphoma, esophageal cancer, small intestine cancer, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, chronic and acute leukemias such as acute myeloid leukemia, chronic myelogenous leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, solid tumors in children, lymphocytic lymphoma, bladder cancer, kidney cancer, ureter cancer, Pelvic carcinoma, ne
- the cancer may be a cancer that expresses CNTN4.
- the cancer may be refractory or resistant to an existing immune checkpoint inhibitor (eg, resistant to a PD-1 pathway inhibitor, a PD-L1 pathway inhibitor, or a CTLA-4 pathway inhibitor).
- an existing immune checkpoint inhibitor eg, resistant to a PD-1 pathway inhibitor, a PD-L1 pathway inhibitor, or a CTLA-4 pathway inhibitor.
- the antibodies or antigen-binding fragments of the present invention may be used alone or in combination with other anti-cancer therapies.
- Other anti-cancer therapies include, for example, standard cancer therapy (eg, chemotherapy, radiation therapy, or surgery); or to other anticancer agents, for example, cytotoxic agents, cytostatic agents, anti-angiogenic or antimetabolic agents, tumor targeting agents, immune stimulating or immune modulators or cytotoxic agents, cytostatic agents, or other toxic agents antibodies, immune checkpoint inhibitors, and the like.
- the antibody or antigen-binding fragment of the present invention can be used in combination therapy with other anti-cancer agents, such as immune checkpoint inhibitors, chemotherapeutic agents, or radiation therapy.
- the immune checkpoint inhibitor is, for example, an anti-CTLA-4 antibody (eg, ipilimumab), an anti-PD-1 antibody (eg, pembrolizumab, nivolumab), or an anti-PD-L1 antibody (eg, atezolizumab, avelumab, durvalumab).
- the chemotherapeutic agents include alkylating agents, antimetabolites, kinase inhibitors, spindle toxic plant alkaloids, cytotoxic/antitumor antibiotics, topoisomerase inhibitors, photosensitizers, antiestrogens and selective estrogen receptor modulators (SERMs), antiprogesterone, estrogen receptor down-regulators (ERDs), estrogen receptor antagonists, luteinizing hormone releasing hormone agonists, anti-androgens, aromatase inhibitors, EGFR inhibitors, VEGF inhibitors, antisense oligonucleotides that inhibit expression of genes implicated in abnormal cell proliferation or tumor growth, but , but not limited thereto.
- SERMs selective estrogen receptor modulators
- ESDs estrogen receptor down-regulators
- estrogen receptor antagonists luteinizing hormone releasing hormone agonists
- anti-androgens aromatase inhibitors
- aromatase inhibitors EGFR inhibitors
- VEGF inhibitors antisense oli
- chemotherapeutic agent of the present invention include gemcitabine, vinorelbine, etoposide (VP-16), platinum analogues such as cisplatin or carboplatin, taxoids such as paclitaxel, albumin -including conjugated paclitaxel, docetaxel, and the like.
- probiotics exhibiting an anticancer effect such as Lactococcus lactis GEN3013 strain (KCTC13426BP), Lactococcus lactis GEN3033 strain (KCTC13684BP), Bifidobacterium bifidum MG731 (Bifidobacterium bifidum MG731) strain (KCTC13452BP) and the like.
- the antibody or antigen-binding fragment of the present invention When used together with other anticancer agents, they may be administered separately or may be applied in the form of a combination product in which a plurality of active ingredients are present in one pharmaceutical formulation. When they are administered as separate agents, the two agents may be administered sequentially or simultaneously. For simultaneous administration, they are given together to the patient. In the case of sequential administration, the time lag may be provided on a not-long-term basis, such as administration to the patient within a period of 12 hours or less, or 6 hours or less.
- the present invention provides a method for preventing, ameliorating or treating an immunosuppression-related disease, such as cancer, comprising administering to the subject an effective amount of an anti-CNTN4 antibody or antigen-binding fragment in combination with an additional anticancer agent.
- an anti-CNTN4 antibody or antigen-binding fragment is simultaneously administered by including an additional anticancer agent in one composition, as well as a composition comprising each of them separately administered simultaneously or sequentially to a patient in need thereof.
- the present invention provides the use of an anti-CNTN4 antibody or antigen-binding fragment thereof in combination with an additional anti-cancer agent for the prevention, amelioration or treatment of an immunosuppression-associated disease, such as cancer.
- the present invention provides a pharmaceutical composition or combination for preventing, ameliorating or treating an immunosuppression-related disease, such as cancer, comprising an anti-CNTN4 antibody or antigen-binding fragment thereof, and an additional anticancer agent.
- a pharmaceutical composition or combination comprising an anti-CNTN4 antibody or antigen-binding fragment thereof, and an additional anticancer agent is used not only when the two components are physically together in the form of one formulation, but also simultaneously or sequentially as separate formulations. or sequential administration, wherein the two drugs may be provided separately or together in one kit.
- the present invention provides a kit for preventing, ameliorating or treating an immunosuppression-related disease, such as cancer, comprising an anti-CNTN4 antibody or antigen-binding fragment thereof, and an additional anticancer agent.
- the additional anticancer agent is preferably an immune checkpoint inhibitor, more preferably an anti-CTLA-4 antibody (eg ipilimumab), an anti-PD-1 antibody (eg pembrolizumab, nivolumab), or an anti-PD-L1 antibody (eg, atezolizumab, avelumab, durvalumab).
- an anti-CTLA-4 antibody eg ipilimumab
- an anti-PD-1 antibody eg pembrolizumab, nivolumab
- an anti-PD-L1 antibody eg, atezolizumab, avelumab, durvalumab.
- Another preferred additional anticancer agent is a chemotherapeutic agent such as gemcitabine, vinorelbine, etoposide (VP-16), platinum analogues such as cisplatin or carboplatin, taxoids such as paclitaxel , albumin-binding paclitaxel, or docetaxel.
- chemotherapeutic agent such as gemcitabine, vinorelbine, etoposide (VP-16), platinum analogues such as cisplatin or carboplatin, taxoids such as paclitaxel , albumin-binding paclitaxel, or docetaxel.
- Another preferred additional anti-cancer therapy used in combination with the antibody or antigen-binding fragment thereof of the present invention includes radiation therapy.
- the present invention also provides a method for detecting the presence of a CNTN4 protein in a sample using the anti-CNTN4 antibody or antigen-binding fragment thereof as an active ingredient, or a method for measuring the amount of the anti-CNTN4 antibody.
- the method includes contacting the antibody or antigen-binding fragment thereof with a sample and a control sample under conditions in which the antibody or antigen-binding fragment thereof can bind to a CNTN4 protein to form a complex. Thereafter, it is detected whether the complex is formed.
- the difference in the degree of complex formation between the samples compared to the control sample is evidence that the human blood antigen is present in the sample (eg, blood).
- the present invention provides a composition for diagnosing cancer comprising the anti-CNTN4 antibody or antigen-binding fragment thereof.
- compositions comprising an anti-CNTN4 antibody or antigen-binding fragment thereof.
- the composition may contain an inactive ingredient, ie, a pharmaceutically acceptable excipient (see Handbook of Pharmaceutical Excipients et al.).
- Compositions of therapeutic and diagnostic agents can be prepared by mixing with physiologically acceptable carriers, excipients or stabilizers, for example in the form of lyophilized powders, slurries, aqueous solutions or suspensions.
- Suitable routes of administration include parenteral administration, eg, intramuscular, intravenous, or subcutaneous administration.
- Administration of the antibody used in the pharmaceutical composition of the present invention or used to practice the method of the present invention is carried out by various conventional methods such as topical application or dermal, subcutaneous, intraperitoneal, parenteral, intraarterial or intravenous injection. can do.
- the antibody of the invention is administered intravenously or subcutaneously.
- Example 1 CNTN4 specific binding scFv antibody selection
- the 15 chickens were divided into 3 groups of 5 each, and the first group was inoculated with mouse CNTN4, the second group with human CNTN4, and the third group with mouse CNTN4 and human CNTN4 were inoculated for a total of 4 times to generate antibodies.
- Antigen immunization dose was 20ug/chicken for each group in the first round, 10ug/chicken at the second round after 3 weeks, 10ug/chicken at the third round after 2 weeks, and 10ug/chicken at the fourth round after 2 weeks.
- blood was collected with a syringe and antibody production was confirmed through ELISA in which serum binds to antigen.
- variable regions of the antibody light and heavy chains and the scFv fragment linking them with a linker were obtained, cloned into a phagemid vector pComb3X with restriction enzyme Sfi I for phage display, and F' capable of infecting M13 helper phage pili-bearing E. coli ER2738 was electroporated.
- the complexity of the scFv library was confirmed as shown in Table 2.
- Anti-chicken CNTN4 scFv library (Number of the binding clones) Chicken number 1-3 1-4 3-2 3-5 Whole blood 1.5 x 10 8 4.0 x 10 8 1.4 x 10 9 9.3 x 10 8 bone marrow - 4.7 x 10 8 9.3 x 10 8 1.5 x 10 9 Spleen 3.5 x 10 8 - - 9.2 x 10 8 Bursa Fabricius 1.2 x 10 9 - - 1.3 x 10 9
- phage is mixed with 50 ⁇ L of protein A and immunoglobulin complex and incubated at 37°C for 1 hour to remove non-specific binding (Fc binder) (Pre-clearing), PBS (pH 7.4) as a binding buffer, or Competitive elution was performed with antigen in the condition of incubation at 37°C for 4 hours using 50 mM sodium acetate (pH 5.5), and in the elution step, washed with 0.5% tween20 in PBS, and then 100 ⁇ L of anti-CNTN4 chicken serum was added.
- Fc binder Pre-clearing
- PBS pH 7.4
- Competitive elution was performed with antigen in the condition of incubation at 37°C for 4 hours using 50 mM sodium acetate (pH 5.5), and in the elution step, washed with 0.5% tween20 in PBS, and then 100 ⁇ L of anti-CNTN4 chicken serum was added.
- a total of four conditions were set through a combination of conditions for adding elution (Table 3). It proceeded from round 1 to round 3 or 5 (antigen 20 ⁇ g ⁇ 1 ⁇ g) while controlling the stringency of the phage binding condition for each condition.
- Phage ELISA was first coated with an antigen (mouse CNTN4 or human CNTN4) on a plate overnight at 4°C, followed by blocking with 3% BSA in PBS for 1 hour. Then, 50 ⁇ L of phage was placed on the antigen-coated plate and incubated for 2 hours.
- ABTS was added to develop color, and absorbance was measured at 405 nm.
- ELISA screening was performed on a total of 950 colonies from Chicken Numbers 1-4 and 3-2 libraries and 380 colonies from Chicken Numbers 1-3 and 3-5 libraries, and 138 each as positive clones binding to the antigen CNTN4. And 306 were selected and 26 and 35 unique scFv sequences were selected through sequencing to confirm the scFv sequence, respectively.
- scFv antibody selected in Example 1.1 For functional evaluation of the scFv antibody selected in Example 1.1, cloning was performed in the form of scFv or human IgG4 (S228P) labeled with constant human kappa (hCk), which is a fusion protein, and transient transfection was performed in Expi293F cells. After binding scFv-hCk or IgG secreted in the culture medium to kappa select, it was purified by pH elution, and after changing to PBS buffer through dialysis, the protein was quantified to obtain scFv-hCk or IgG.
- S228P human IgG4
- hCk constant human kappa
- SEQ ID NO: 1 S1 light chain variable region (VL) ALTQPSSVSANPGETVKITCSGGSSYGWYQQKSPGSAPVTVIYDNTNRPSNIPSRFSGSKSGSTNTLTITGVRAEDEAVYFCGGYDSSIDAFGAGTTLTVL
- SEQ ID NO: 2 S1 heavy chain variable region (VH) AVTLDESEGGLQTPGGALSLVCKASGFTFSSFNMFWVRQAPGKGLEYVAEISGGGGSTWYAPAVKGRATISRDNGQSTVRLQLNNLRAEDTGTYYCAKSADTWSYGAATIDAWGHGTEVIVSS
- SEQ ID NO: 3 S2 light chain variable region (VL) ALTQPSSVSANPGETVKITCSGGGSSTYYGWYQQKSPGSAPVTVIYNNNNRPSDIPSRFSGSGSTGTLTITGVRAEDEAVYYCGGYDGSTDVFGAGTTLTVL
- SEQ ID NO: 2 S2 heavy chain variable region (VH)
- Human CNTN4 antigen was expressed on the cell membrane through transient transfection in 293FT cells, and anti-CNTN4 scFv-hCk or Anti-CNTN4 IgG was bound at a concentration of 40 ⁇ g/mL. The dot shift was confirmed by detecting anti-CNTN4 bound to the antigen with anti-hCk-PE or anti-hFc-PE using FACS.
- Example 2 Anti-CNTN4 chicken-human chimeric IgG4 antibody production and binding affinity confirmation
- An ELISA test was performed for A-01 prepared in Example 2.1. 200 ng of antigen (human CNTN4-10xHis or mouse CNTN4-10xHis) was coated on an ELISA plate. For antibody binding, serial dilution of A-01 at a maximum of 1 ⁇ M was diluted to 0.0001 nM and bound to antigen. Anti-human Fc-HRP was used as a secondary antibody for antibody detection. The color was developed using ABTS, a color developing reagent, and absorbance at 405 nm was measured. The binding capacity thereof is shown in Table 10.
- CM5 chip in order to bind anti-human IgG Fc (capture antibody) using amine coupling, a CM5 chip was installed, a running buffer was flowed to activate the chip, and then a capture antibody was attached. After inactivation of dextrin to which no capture antibody was attached using ethanolamine, regeneration was performed using 3M magnesium chloride to remove analytes except for the capture antibody. A-01 prepared at a concentration of 0.05 ⁇ g/mL was flowed for 30 seconds at a rate of 10 ⁇ L/min for binding.
- human CNTN4 400nM ⁇ 0.78nM prepared by sequential dilution as an antigen was flowed at a rate of 30 ⁇ L/min for 3 minutes to bind and dissociate for 5 minutes. Thereafter, regeneration was performed by flowing a regeneration solution (3M magnesium chloride) at a rate of 20 ⁇ L/min for 30 seconds to remove all analytes attached to the capture antibody. The sequence of A-01 binding, antigen binding, dissociation, and regeneration was repeated for each concentration of antigen. The results are shown in Table 11.
- the antibody of the present invention binds to human CNTN4 protein with high affinity.
- Humanized antibody was prepared using A-01.
- VLA and VHA variable region original sequence
- VL1 and VH1 a sequence in which the framework region was completely replaced with a human framework region in the variable region original sequence (VLA and VHA) of A-01
- VL2 and VH2 a sequence that left some of the original sequence of A-01 in VL1 and VH1
- VL1 and VH1 a sequence that left some of the original sequence of A-01 in VL1 and VH1
- VL2 and VH2 VH2
- VH2 and VH2 fully humanized antibody
- the LAH2, L1H2, and L2H2 antibodies prepared in Example 3.1 were subjected to an ELISA test together with A-01. 200ng of antigen (human CNTN4-10xHis or mouse CNTN4-10xHis) was coated on an ELISA plate. For antibody binding, serial dilution of the antibody at a maximum of 1 ⁇ M was diluted to 0.0001 nM and bound to the antigen. Anti-human Fc-HRP was used as a secondary antibody for antibody detection. The color was developed using ABTS, a color developing reagent, and the absorbance at 405 nm was measured.
- the binding capacity thereof is shown in Table 13.
- Table 13 In the case of the most humanized L1H2, it was confirmed that the difference in binding ability with the CNTN4 protein was within 3 times compared to the A-01 origin.
- the SPR test was performed on L1H2, which was the most humanized with about 98%. More specifically, in order to bind anti-human IgG Fc (capture antibody) using amine coupling, a CM5 chip was installed, a running buffer was flowed to activate the chip, and then a capture antibody was attached. Dextrin to which no capture antibody was attached was inactivated using ethanolamine, and then regeneration was performed using 3M magnesium chloride to remove analytes except for the capture antibody. L1H2 prepared at a concentration of 0.05 ⁇ g/mL was flowed for 30 seconds at a rate of 10 ⁇ L/min for binding.
- L1H2 prepared at a concentration of 0.05 ⁇ g/mL was flowed for 30 seconds at a rate of 10 ⁇ L/min for binding.
- human CNTN4 400nM ⁇ 0.78nM prepared by sequential dilution as an antigen was flowed at a rate of 30 ⁇ L/min for 3 minutes to bind and dissociate for 5 minutes. Thereafter, regeneration was performed by flowing a regeneration solution (3M magnesium chloride) at a rate of 20 ⁇ L/min for 30 seconds to remove all analytes attached to the capture antibody. For each concentration of antigen, the sequence of L1H2 binding, antigen binding, dissociation, and regeneration was repeated.
- the A-01 antibody has a sufficiently high binding affinity to the CNTN4 protein even when it is 98% humanized.
- Example 4 CNTN4 neutralizing ability test using human T cells of A-01 and L1H2 antibodies
- a final 50 mL of a-CD3 antibody at a concentration of 4 mg/mL and CNTN4 recombinant protein at a concentration of 150 nM were put into a 96-well plate and incubated at 37° C. for about 16 hours.
- the PBMC cells obtained in the above experiment were resuspended by adding 1,000 ⁇ L of MACS buffer per 2 X 10 8 cells. The solution was divided in half, and one half was put in a CD4 tube and one half in a CD8 tube. For each group of PBMC 1 X 10 8 , 50 ⁇ L of antibody cocktail was added, resuspended, and stored at room temperature for 10 minutes. 100 ⁇ L of anti-biotin microbead per PBMC 1 X 10 8 was added, resuspended, and stored at room temperature for 10 minutes. Meanwhile, the MACS magnetic field was sterilized and placed in a clean bench to install two LS columns (for CD4 and for CD8).
- the incubated plate was washed twice with 200 ⁇ l of PBS, and 1.5 mM and 3 mM, respectively, of A-01 and L1H2 were added to a final 50 mL of CNTN4-treated wells into a 96-well plate. Incubated at 37° C. for about 4 hours.
- the incubated plate was washed twice with 200 mL of PBS, and 200 mL of T cells were added to each well, and then stored in a 5% CO 2 incubator at 37° C. for 3 days. After 3 days, T cells were obtained and transferred to a FACS tube, and the degree of CFSE-stained cell differentiation was observed using a FACS instrument.
- the CNTN4 antibody of the present invention effectively neutralized CNTN4 and suppressed its T cell inhibitory function.
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Anti-chicken CNTN4 scFv library (Number of the binding clones) |
||||
Chicken number | 1-3 | 1-4 | 3-2 | 3-5 |
Whole blood | 1.5 x 108 | 4.0 x 108 | 1.4 x 109 | 9.3 x 108 |
Bone marrow | - | 4.7 x 108 | 9.3 x 108 | 1.5 x 109 |
Spleen | 3.5 x 108 | - | - | 9.2 x 108 |
Bursa Fabricius | 1.2 x 109 | - | - | 1.3 x 109 |
조건 | A | B | C | D |
Pre-clearing | Yes | No | No | No |
Binding buffer | PBS (pH 7.4) | PBS (pH 7.4) | PBS (pH 7.4) | 50mM Sodium acetate (pH 5.5) |
Elution | 항원 & Serum | 항원 & Serum | 항원 | 항원 & Serum |
서열번호 | 영역 | 서열 |
서열번호 1 | S1 경쇄 가변 영역(VL) | ALTQPSSVSANPGETVKITCSGGSSYGWYQQKSPGSAPVTVIYDNTNRPSNIPSRFSGSKSGSTNTLTITGVRAEDEAVYFCGGYDSSIDAFGAGTTLTVL |
서열번호 2 | S1 중쇄 가변 영역(VH) | AVTLDESEGGLQTPGGALSLVCKASGFTFSSFNMFWVRQAPGKGLEYVAEISGGGGSTWYAPAVKGRATISRDNGQSTVRLQLNNLRAEDTGTYYCAKSADTWSYGAATIDAWGHGTEVIVSS |
서열번호 3 | S2 경쇄 가변 영역(VL) | ALTQPSSVSANPGETVKITCSGGGSSTYYGWYQQKSPGSAPVTVIYNNNNRPSDIPSRFSGSGSGSTGTLTITGVRAEDEAVYYCGGYDGSTDVFGAGTTLTVL |
서열번호 2 | S2 중쇄 가변 영역(VH) | AVTLDESEGGLQTPGGALSLVCKASGFTFSSFNMFWVRQAPGKGLEYVAEISGGGGSTWYAPAVKGRATISRDNGQSTVRLQLNNLRAEDTGTYYCAKSADTWSYGAATIDAWGHGTEVIVSS |
서열번호 4 | S3 경쇄 가변 영역(VL) | ALTQPSSVSANPGETVKITCSGGSSYGWYQQKAPGSAPVTLIYDNTNRPSNIPSRFSGSTSGSTGTLTITGVRAEDEAVYFCGGYDGSTDAFGAGTTLTVL |
서열번호 2 | S3 중쇄 가변 영역(VH) | AVTLDESEGGLQTPGGALSLVCKASGFTFSSFNMFWVRQAPGKGLEYVAEISGGGGSTWYAPAVKGRATISRDNGQSTVRLQLNNLRAEDTGTYYCAKSADTWSYGAATIDAWGHGTEVIVSS |
서열번호 5 | S4 경쇄 가변 영역(VL) | ALTQPSSVSANPGESVKITCSGGGSSYYGWYQQKSPGSAPVTLIYQNTNRPSNIPSRFSGSGSGSTGTLTITGVRAEDEAVYYCGGYDGSTDVFGAGTTLTVL |
서열번호 6 | S4 중쇄 가변 영역(VH) | AVTLDESEGGLQTPGGALSLVCKASGFTFSSFNMFWVRQAPGKGLEYVAEISGGGGSTWYASAVKGRATISRDNGQSTVRLQLNNLRAEDTGTYYCAKSADTWSYGAATIDAWGHGTEVIVSS |
서열번호 7 | S6 경쇄 가변 영역(VL) | ALTQPSSVSANPGETVKITCSGGSGNYGWYQQKSPGSAPVTVIYNGNNRPSDIPSRFSGSGSGSTNTLAITGVQAEDEAVYFCGGYDGTIDAFGAGTTLTVL |
서열번호 2 | S6 중쇄 가변 영역(VH) | AVTLDESEGGLQTPGGALSLVCKASGFTFSSFNMFWVRQAPGKGLEYVAEISGGGGSTWYAPAVKGRATISRDNGQSTVRLQLNNLRAEDTGTYYCAKSADTWSYGAATIDAWGHGTEVIVSS |
서열번호 8 | S7 경쇄 가변 영역(VL) | ALTQPSSVSANPGETVEITCSGGSGSYGWYQQKAPGSAPVTVIYDNTNRPSNIPSRFSGSGSDSTGTLTITGVQADDEAVYYCGSYDSIEVIFGAGTTLTVL |
서열번호 9 | S7 중쇄 가변 영역(VH) | AVTLDESGGGLHTPGGALSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 8 | S8 경쇄 가변 영역(VL) | ALTQPSSVSANPGETVEITCSGGSGSYGWYQQKAPGSAPVTVIYDNTNRPSNIPSRFSGSGSDSTGTLTITGVQADDEAVYYCGSYDSIEVIFGAGTTLTVL |
서열번호 9 | S8 중쇄 가변 영역(VH) | AVTLDESGGGLHTPGGALSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 8 | S9 경쇄 가변 영역(VL) | ALTQPSSVSANPGETVEITCSGGSGSYGWYQQKAPGSAPVTVIYDNTNRPSNIPSRFSGSGSDSTGTLTITGVQADDEAVYYCGSYDSIEVIFGAGTTLTVL |
서열번호 9 | S9 중쇄 가변 영역(VH) | AVTLDESGGGLHTPGGALSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 8 | S10 경쇄 가변 영역(VL) | ALTQPSSVSANPGETVEITCSGGSGSYGWYQQKAPGSAPVTVIYDNTNRPSNIPSRFSGSGSDSTGTLTITGVQADDEAVYYCGSYDSIEVIFGAGTTLTVL |
서열번호 9 | S10 중쇄 가변 영역(VH) | AVTLDESGGGLHTPGGALSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 8 | S11 경쇄 가변 영역(VL) | ALTQPSSVSANPGETVEITCSGGSGSYGWYQQKAPGSAPVTVIYDNTNRPSNIPSRFSGSGSDSTGTLTITGVQADDEAVYYCGSYDSIEVIFGAGTTLTVL |
서열번호 9 | S11 중쇄 가변 영역(VH) | AVTLDESGGGLHTPGGALSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 8 | S15 경쇄 가변 영역(VL) | ALTQPSSVSANPGETVEITCSGGSGSYGWYQQKAPGSAPVTVIYDNTNRPSNIPSRFSGSGSDSTGTLTITGVQADDEAVYYCGSYDSIEVIFGAGTTLTVL |
서열번호 9 | S15 중쇄 가변 영역(VH) | AVTLDESGGGLHTPGGALSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 8 | S24 경쇄 가변 영역(VL) | ALTQPSSVSANPGETVEITCSGGSGSYGWYQQKAPGSAPVTVIYDNTNRPSNIPSRFSGSGSDSTGTLTITGVQADDEAVYYCGSYDSIEVIFGAGTTLTVL |
서열번호 10 | S24 중쇄 가변 영역(VH) | AVTLDESGGGLHTPGGALSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGGDSDSIDAWGHGTEVIVSS |
서열번호 8 | S30 경쇄 가변 영역(VL) | ALTQPSSVSANPGETVEITCSGGSGSYGWYQQKAPGSAPVTVIYDNTNRPSNIPSRFSGSGSDSTGTLTITGVQADDEAVYYCGSYDSIEVIFGAGTTLTVL |
서열번호 9 | S30 중쇄 가변 영역(VH) | AVTLDESGGGLHTPGGALSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 11 | S46 경쇄 가변 영역(VL) | ALTQPSSVSANPGETVEITCSGGSGSYGWYQQKAPGSAPVTVIYDNTNRPSNIPSRFSGSGSDSTGTLTITGVQADDKAVYYCGSYDSIEVIFGAGTTLTVL |
서열번호 9 | S46 중쇄 가변 영역(VH) | AVTLDESGGGLHTPGGALSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 12 | S83 경쇄 가변 영역(VL) | ALTQPSSVSANLGETVKITCSGGGGYSGSYYYGWYQQKSPAGAPDTVIYSNNQRPSNIPSRFSGSKSGSTGTLTITEDHAEDEAVYYCGSIDSSSNPGIFGAGTTLTVL |
서열번호 13 | S83 중쇄 가변 영역(VH) | AVTLDKSGGGLHTPGGALSLVCKASGFTFSRYIMQWVLQAPGKVLEWVASIRNGTTPKYGAAVKGRATISRDNGQSTVMLQLNSLTYDDTDAYYCDRGDDGDCICGGCAASIDIWCYATEVIVSS |
서열번호 14 | S96 경쇄 가변 영역(VL) | ALTQPSSVSANPGETVKITCSGSSGSYGYSWHQQKSPGSAPVTVIYESNKRPSNIPSRFSGSTSGSTSTLTITGVQADDEAVYFCGSADSSTTIAFGAGTTLTVL |
서열번호 15 | S96 중쇄 가변 영역(VH) | AVTLDESGGGLQTPGGTLSLVCKASGFTFSTYSMQWLRQAPGKGLEWVAGISNSGSSTVYGPAVKGRATISRDNGQSTVSLQLNNLRAEDTGTYYCAKSTYGGSWYAAYSIDEWGHGTEVIVSS |
서열번호 16 | S99 경쇄 가변 영역(VL) | ALTQPSSVSANPGETVKITCSGGASYAGNYYYGWYQQKSPGSAPVTVIYNNNQRPSDIPSRFSGSLSGSTNTLTITGVQADDEAVYFCGSDDSSAGYTGIFGAGTTLTVL |
서열번호 17 | S99 중쇄 가변 영역(VH) | AVTLDESGGGLQTPGGALSLVCKASEFTFSGYGMHWVRQAPGKGLEFVAEISNTGSWTGYGAAVKGRATISRDNGQSTVRLQLNNLKADDTATYYCAKVGGRGWCGRSGCADDIDAWGHGTEVIVSS |
서열번호 18 | S129 경쇄 가변 영역(VL) | ALTQPSSVSANLGETVKITCSGSSGSYGWYQQKSPGSAPVTLIYDNTNRPSDIPSRFSGSGSGSTGTLTITGVRAEDEAVYYCGGYDGSTDVFGAGTTLTVL |
서열번호 2 | S129 중쇄 가변 영역(VH) | AVTLDESEGGLQTPGGALSLVCKASGFTFSSFNMFWVRQAPGKGLEYVAEISGGGGSTWYAPAVKGRATISRDNGQSTVRLQLNNLRAEDTGTYYCAKSADTWSYGAATIDAWGHGTEVIVSS |
서열번호 3 | S130 경쇄 가변 영역(VL) | ALTQPSSVSANPGETVKITCSGGGSSTYYGWYQQKSPGSAPVTVIYNNNNRPSDIPSRFSGSGSGSTGTLTITGVRAEDEAVYYCGGYDGSTDVFGAGTTLTVL |
서열번호 2 | S130 중쇄 가변 영역(VH) | AVTLDESEGGLQTPGGALSLVCKASGFTFSSFNMFWVRQAPGKGLEYVAEISGGGGSTWYAPAVKGRATISRDNGQSTVRLQLNNLRAEDTGTYYCAKSADTWSYGAATIDAWGHGTEVIVSS |
서열번호 19 | S131 경쇄 가변 영역(VL) | ALTQPSSVSANLGGTVKITCSGGGSSYYGWYQQKSPGSAPVTLIYQNTNRPSNIPSRFSGSGSGSTGTLTITGVRAEDEAVYYCGGYDGSTDVFGAGTTLTVL |
서열번호 2 | S131 중쇄 가변 영역(VH) | AVTLDESEGGLQTPGGALSLVCKASGFTFSSFNMFWVRQAPGKGLEYVAEISGGGGSTWYAPAVKGRATISRDNGQSTVRLQLNNLRAEDTGTYYCAKSADTWSYGAATIDAWGHGTEVIVSS |
서열번호 3 | S132 경쇄 가변 영역(VL) | ALTQPSSVSANPGETVKITCSGGGSSTYYGWYQQKSPGSAPVTVIYNNNNRPSDIPSRFSGSGSGSTGTLTITGVRAEDEAVYYCGGYDGSTDVFGAGTTLTVL |
서열번호 20 | S132 중쇄 가변 영역(VH) | AVTLDESGGGLQTPGGALSLVCKASGFTFSSFNMFWVRQAPGKGLEYVAEISGGGGSTWYAPAVKGRATISRDNGQSTVRLQLNNLRAEDTGTYYCAKSADTWSYGAATIDAWGHGTEVIVSS |
서열번호 21 | S134 경쇄 가변 영역(VL) | ALTQPSSVSANPGETVKITCSGGTYSYGNYYYGWYQQKSPGSAPVTVIYNNNNRPSDIPSRFSGSGSGSTGTLTITGVRAEDEAVYYCGGYDGSTDVFGAGTTLTVL |
서열번호 2 | S134 중쇄 가변 영역(VH) | AVTLDESEGGLQTPGGALSLVCKASGFTFSSFNMFWVRQAPGKGLEYVAEISGGGGSTWYAPAVKGRATISRDNGQSTVRLQLNNLRAEDTGTYYCAKSADTWSYGAATIDAWGHGTEVIVSS |
서열번호 22 | S135 경쇄 가변 영역(VL) | ALTQPSSVSANPGETVKITCSGGGSSSYYGWYQQKSPGSAPVTVIYYNNRPSDIPSRFSGSGSGSTGTLTITGVRAEDEAVYYCGGYDGSTDVFGAGTTLTVL |
서열번호 2 | S135 중쇄 가변 영역(VH) | AVTLDESEGGLQTPGGALSLVCKASGFTFSSFNMFWVRQAPGKGLEYVAEISGGGGSTWYAPAVKGRATISRDNGQSTVRLQLNNLRAEDTGTYYCAKSADTWSYGAATIDAWGHGTEVIVSS |
서열번호 23 | S137 경쇄 가변 영역(VL) | ALTQPSSVSANPGETVKITCSGGSSYGWYQQKSPGSAPVTVIYDNTNRPSNIPSRFSGSKSGSTNTLTITGVQAEDEAVYYCGGYDGSTDAFGAGTTLTVL |
서열번호 2 | S137 중쇄 가변 영역(VH) | AVTLDESEGGLQTPGGALSLVCKASGFTFSSFNMFWVRQAPGKGLEYVAEISGGGGSTWYAPAVKGRATISRDNGQSTVRLQLNNLRAEDTGTYYCAKSADTWSYGAATIDAWGHGTEVIVSS |
서열번호 24 | S138 경쇄 가변 영역(VL) | ALTQPSSVSANPGETVNITCSGGGSYAGSYYYGWYQQKAPGSAPVTVIYDSTNRPSNIPSRFSGSLSGSTNTLTITGVRAEDEAVYYCGGYDGSTDVFGAGTTLTVL |
서열번호 2 | S138 중쇄 가변 영역(VH) | AVTLDESEGGLQTPGGALSLVCKASGFTFSSFNMFWVRQAPGKGLEYVAEISGGGGSTWYAPAVKGRATISRDNGQSTVRLQLNNLRAEDTGTYYCAKSADTWSYGAATIDAWGHGTEVIVSS |
서열번호 | 영역 | 서열 |
서열번호 25 | A13WB2 경쇄 가변 영역(VL) | ALTQPSSVSANLGGTVEITCSGGYSGYGWYQQKSPGSAPVTLIYYNDKRPSDIPSRFSGSKSGSTGTLTITGVQAEDEAVYFCGSRDSSTYVDIFGAGTTLTVL |
서열번호 9 | A13WB2 중쇄 가변 영역(VH) | AVTLDESGGGLHTPGGALSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 26 | A13WB4 경쇄 가변 영역(VL) | ALTQPSSVSANPGETVEITCSGGSSDYGYGWYQQKSPGSAPVTVIYYNNNRPSDIPSRFSGSLSGSTNTLTITGVQADDEAVYFCGSRDSSSGYVDIFGAGTTLTVL |
서열번호 9 | A13WB4 중쇄 가변 영역(VH) | AVTLDESGGGLHTPGGALSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 27 | A13WB7 경쇄 가변 영역(VL) | ALTQPSSVSANPGETVKITCSGGGSSSYYNYGWYQQKSPGSAPVTVIYYNDKRPSDIPSRFSGSKSGSTGTLTITGVQAEDEAVYYCGSWDSSTYSDIFGAGTTLTVL |
서열번호 9 | A13WB7 중쇄 가변 영역(VH) | AVTLDESGGGLHTPGGALSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 28 | A13WB24 경쇄 가변 영역(VL) | ALTQPSSVSANPGGTVEITCSGGGNNNYGWYQQKSPGSAPVTLIYYNDNRPSDIPSRFSGSKSGSTATLTITGVQAEDEAVYYCGGYDISYVDIFGAGTTLTVL |
서열번호 9 | A13WB24 중쇄 가변 영역(VH) | AVTLDESGGGLHTPGGALSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 29 | A13WB25 경쇄 가변 영역(VL) | ALTQPSSVSANLGGTVEITCSGGGGSYGWYQQKSPGSAPVTVIYYNDKRPSDIPSRFSGSKSGSTGTLTITGVQAEDEAVYFCGGYDGSTYAGIFGAGTTLTVL |
서열번호 9 | A13WB25 중쇄 가변 영역(VH) | AVTLDESGGGLHTPGGALSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 30 | A13WB73 경쇄 가변 영역(VL) | ALTQPSSVSANLGGTVEITCSGGYSGYGWYQQMSPGSAPVTLTYYNDKRPSNIPSRFSGSKSGSTATLAITGVQAEDEAVYYCGSWDTSTNTPIFGAGTTLTVL |
서열번호 31 | A13WB73 중쇄 가변 영역(VH) | AVTLDESGGGLHTPGGVLSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 32 | A13SF1 경쇄 가변 영역(VL) | ALTQPSSVSANLGGTVKITCSGGGGSYGWFQQKSPGSAPVTLIYNNNNRPSDIPSRFSGSKSGSTATLTITGVQAEDEAVYFCGGYDSSTYVGTFGAGTTLTVL |
서열번호 33 | A13SF1 중쇄 가변 영역(VH) | AVTLDESGGGLQTPGGGLSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 34 | A13SF2 경쇄 가변 영역(VL) | ALTQPSSVSANLGGTVKITCSGGGGSYGWYRQKSPGSAPVTLIYNNNNRPSDIPSRFSGSTSGSTGTLTITGVQADDEAVYFCGGYDSSAGYAALFGAGTTLTVL |
서열번호 35 | A13SF2 중쇄 가변 영역(VH) | AVTLDESGGGLQTPGGALSLICKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 36 | A13SF7 경쇄 가변 영역(VL) | ALTQPSSVSANLGGTVEITCSGGSGSYGWYQQKSPGSAPVTLIYDNTNRPSNIPSRFSGSTSGSTSTLTITGVQADDEAVYFCGSADTNAAYAAIFGAGTTLTVL |
서열번호 9 | A13SF7 중쇄 가변 영역(VH) | AVTLDESGGGLHTPGGALSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 37 | A13SF8 경쇄 가변 영역(VL) | ALTQPSSVSANPGGTVKITCSGSGNYGWYQQKSPGSALVTVIYYNDKRPSDIPSRFSGSTSGSTGTLTITGVQVEDEAVYYCGGYDGYSFASIFGAGTTLTVL |
서열번호 9 | A13SF8 중쇄 가변 영역(VH) | AVTLDESGGGLHTPGGALSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 38 | A13SF16 경쇄 가변 영역(VL) | ALTQPSSVSANLGGTVKITCSGSGGSYGWFQQKSPGSAPVTLIYNNDNRPSDIPSRFSGSKSGSTATLTITGVQAEDEAVYFCGGYDSSTYVDTFGAGTTLTVL |
서열번호 33 | A13SF16 중쇄 가변 영역(VH) | AVTLDESGGGLQTPGGGLSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 39 | A13SF19 경쇄 가변 영역(VL) | ALTQPSSVSANLGGTVEITCSGSSSGNYGWYQQKSPGSAPVTVIYYNDERPSDIPSRFSGSKSGSTGTLTITGVQAEDEAVYYCGGYEGSTYVGIFGAGTTLTVL |
서열번호 40 | A13SF19 중쇄 가변 영역(VH) | AVTLDESGGGLHTPGGALSLVCKASGFTFSSYGMAWVRQASGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 41 | A13SF20 경쇄 가변 영역(VL) | ALTQPSSVSANLGGTVEITCSGGSGSYGWYQQKAPGSAPVTLIYNSDKRPSDIPSRFSGSKSGSTGTLTITGVQAEDEAVYFCGGYDSSAIFGAGTTLTVL |
서열번호 9 | A13SF20 중쇄 가변 영역(VH) | AVTLDESGGGLHTPGGALSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 42 | A13SF21 경쇄 가변 영역(VL) | ALTQPSSVSANLGGTVEITCSGSSGSYGWYQQKAPGSAPVTVIYNNNNRPSGIPSRFSGALSGSTATLTITGVQAEDEAVYFCGGYDSSTYVGIFGAGTTLTVL |
서열번호 9 | A13SF21 중쇄 가변 영역(VH) | AVTLDESGGGLHTPGGALSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 43 | A13SF74 경쇄 가변 영역(VL) | ALTQPSSVSANPGETVKITCSGNSSGCSWYGWFQQKSPGSALVTVIYDNTNRPSNIPSRFSGSRSGSTATLTITGVQAEDEAIYFCGIADSSGAGIFGAGTTLTVL |
서열번호 44 | A13SF74 중쇄 가변 영역(VH) | AVTLDESGGGLQTPGGALSLVCKASGFTLSSYAMQWVRQAPGKGLEWVAGISKGGGSTAYGAAVKGRATISRDNGQSTVRLQLNNLRAEDTATYFCAKTTDSNCCSSDSIDAWGHGTEVIVSS |
서열번호 45 | A35WB1 경쇄 가변 영역(VL) | ALTQPSSVSANPGETVKITCSGGSGSYGWYQQKSPGSAPVTVIYNNDQRPSNIPSRFSGSKSGSTATLTITGVQVEDEAVYFCGGWDSNSGAIFGAGTTLTVL |
서열번호 9 | A35WB1 중쇄 가변 영역(VH) | AVTLDESGGGLHTPGGALSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 46 | A35WB27 경쇄 가변 영역(VL) | ALTQPSSVSANLGETVKITCSGGYSGYGWYQQKSPGSAPVTVIYYNDKRPSDIPSRFSGSKSGSTGTLTITGVRAEDEAVYFCGSADSSTGYVAIFGAGTTLTVL |
서열번호 9 | A35WB27 중쇄 가변 영역(VH) | AVTLDESGGGLHTPGGALSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 47 | A35SF3 경쇄 가변 영역(VL) | ALTQPSSVSANLGGTVEITCSGSSGSYGWYQQKAPGSAPVTVIYDNTNRPSDIPSRFSGSKSGSTGTLTITGVQAEDEAVYFCGGYDSSTIFGAGTTLTVL |
서열번호 33 | A35SF3 중쇄 가변 영역(VH) | AVTLDESGGGLQTPGGGLSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 48 | A35SF5 경쇄 가변 영역(VL) | ALTQPSSVSANPGETVEITCSGSSGSNYGWYQQKSPGSAPVTLIYYNDNRPSDIPSRFSGSKSGSTGTLTITGVQVEDEAVYYCGAWESSSNPDIFGAGTTLTVL |
서열번호 9 | A35SF5 중쇄 가변 영역(VH) | AVTLDESGGGLHTPGGALSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 49 | A35SF8 경쇄 가변 영역(VL) | ALTQPSSVSANLGGTVKITCSGGGGSYGWFQQKSPGSAPVTLIYNNNNRPSDIPSRFSGSKSGSTATLTITGVQAEDEAVYFCGGYDDSTYVGMFGAGTTLTVL |
서열번호 9 | A35SF8 중쇄 가변 영역(VH) | AVTLDESGGGLHTPGGALSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 50 | A35SF13 경쇄 가변 영역(VL) | ALTQPSSVSANPGETVKITCSGGGGSYGWYQQKSPGSALVTVIYNNDNRPSNIPSRLSGSKSGSTATLTITGVRAEDEAVYFCGSADNNGYIAIFGAGTTLTVL |
서열번호 9 | A35SF13 중쇄 가변 영역(VH) | AVTLDESGGGLHTPGGALSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 51 | A35SF14 경쇄 가변 영역(VL) | ALTQPSSVSANPGETIKITCSGGGGSYGWYQQKSPGSAPVTVIYNGNNRPSDIPSRFSGSKSGSTATLTITGVQAEDEAVYFCGGYDSGTYSGIFGAGTTLTVL |
서열번호 9 | A35SF14 중쇄 가변 영역(VH) | AVTLDESGGGLHTPGGALSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 52 | A35SF37 경쇄 가변 영역(VL) | ALTQPSSVSANLGGTVKITCSGGSNNYGWYQQKSPGSAPVTVIYYNNKRPSDIPSRFSGSKSGSTATLTITGVQAEDEAVYFCGGYDSSSNSDVYGAGTTLTVL |
서열번호 9 | A35SF37 중쇄 가변 영역(VH) | AVTLDESGGGLHTPGGALSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 53 | A35SF38 경쇄 가변 영역(VL) | ALTQPSSVSANLGGTVKLTCSGSSGSYGWYQQKSPGSAPVTLIYNNNNRPSDIPSRFSGSTSGSTGTLTITGVRAEDEAVYFCGGYDSSTYVAIFGAGTTLTVL |
서열번호 9 | A35SF38 중쇄 가변 영역(VH) | AVTLDESGGGLHTPGGALSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 54 | A35SF39 경쇄 가변 영역(VL) | ALTQPSSVSANLGGTVKITCSGGSGSYGWYQQKSPGSAPVTVIYNNNNRPSDIPSRFSGSTSGSTGTLTITGVRAEDEAVYFCGGYDTDSPIFGAGTTLTVL |
서열번호 9 | A35SF39 중쇄 가변 영역(VH) | AVTLDESGGGLHTPGGALSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 55 | A35SF75 경쇄 가변 영역(VL) | ALTQPSSVSANPGVTVKITCSGGGGSYGWYQQKAPGSAPVTLIYNNTNRPSDIPSRFSGSRSGSTNTLTITGVQAEDEAVYFCGGYDSNTDYVGFGAGTTLTVL |
서열번호 9 | A35SF75 중쇄 가변 영역(VH) | AVTLDESGGGLHTPGGALSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
서열번호 56 | A35SF90 경쇄 가변 영역(VL) | ALTQPSSVSANLGGTVEITCSGSNNNNYGWYQQKTPGSAPVTLIYNNNQRPSDIPSRFSGSKSGSTGTLTITGVRAEDEAVYYCGGYDSSIYFDIFGAGTTLTVL |
서열번호 9 | A35SF90 중쇄 가변 영역(VH) | AVTLDESGGGLHTPGGALSLVCKASGFTFSSYGMAWVRQAPGKGLEWVAGITSSGSSAGYGPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKDGYIYSGADSDSIDAWGHGTEVIVSS |
EC50, nM | Negative control | Human CNTN4 | Mouse CNTN4 |
S1 | N/A | 4.44 | 1.53 |
S2 | N/A | 0.12 | 0.10 |
S4 | N/A | 2.60 | 1.15 |
S6 | N/A | 0.37 | 1.85 |
S7 | N/A | 1.51 | 1.20 |
S8 | N/A | 1.10 | 1.53 |
S9 | N/A | 0.08 | 0.09 |
S10 | N/A | 1.82 | 7.00 |
S11 | N/A | 1.44 | 2.39 |
S15 | N/A | 1.35 | 2.12 |
S24 | N/A | 1.12 | 2.07 |
S30 | N/A | 1.15 | 1.12 |
S46 | N/A | 1.22 | 1.20 |
S99 | N/A | 8.34 | 3.64 |
S129 | N/A | 0.55 | 0.37 |
S130 | N/A | 0.81 | 0.46 |
S131 | N/A | 0.74 | 0.56 |
S132 | N/A | 1.16 | 0.72 |
S134 | N/A | 0.75 | 0.75 |
S135 | N/A | 1.06 | 0.71 |
S137 | N/A | 0.41 | 0.52 |
S138 | N/A | 2.37 | 1.06 |
EC50, nM | Negative control | Human CNTN4 | Mouse CNTN4 |
A13WB2 | N/A | 0.01 | 0.01 |
A13WB4 | N/A | 0.01 | 0.01 |
A13WB7 | N/A | 0.01 | 0.01 |
A13WB24 | N/A | 0.01 | 0.01 |
A13WB25 | N/A | 0.01 | 0.01 |
A13WB73 | N/A | 0.01 | 0.01 |
A13SF1 | N/A | 0.01 | 0.02 |
A13SF2 | N/A | 0.01 | 0.01 |
A13SF7 | N/A | 0.01 | 0.01 |
A13SF8 | N/A | 0.01 | 0.01 |
A13SF16 | N/A | 0.01 | 0.01 |
A13SF19 | N/A | 0.01 | 0.01 |
A13SF20 | N/A | 0.01 | 0.01 |
A13SF21 | N/A | 0.01 | 0.01 |
A13SF74 | N/A | 0.11 | 0.12 |
A35WB1 | N/A | 0.02 | 0.01 |
A35WB27 | N/A | 0.01 | 0.01 |
A35SF3 | N/A | 0.01 | 0.01 |
A35SF5 | N/A | 0.01 | 0.01 |
A35SF8 | N/A | 0.01 | 0.02 |
A35SF13 | N/A | 0.01 | 0.02 |
A35SF14 | N/A | 0.01 | 0.01 |
A35SF37 | N/A | 0.01 | 0.01 |
A35SF38 | N/A | 0.01 | 0.01 |
A35SF39 | N/A | 0.01 | 0.01 |
A35SF75 | N/A | 0.21 | 0.20 |
A35SF90 | N/A | 0.01 | 0.01 |
Shift % | Un-transfected cell | Human CNTN4 transfected cell |
Secondary antibody only | 1.11 | 0.48 |
S1 | 0.21 | 13.8 |
S2 | 0.26 | 15.1 |
S3 | 0.18 | 13.9 |
S4 | 0.20 | 15.4 |
S6 | 0.22 | 14.7 |
S7 | 0.20 | 6.42 |
S8 | 0.21 | 12.9 |
S9 | 0.22 | 4.09 |
S10 | 0.21 | 6.95 |
S11 | 0.20 | 5.29 |
S15 | 0.23 | 6.66 |
S24 | 0.28 | 5.63 |
S30 | 0.24 | 6.87 |
S46 | 0.19 | 8.19 |
S83 | 0.13 | 5.27 |
S96 | 0.25 | 1.69 |
S99 | 3.75 | 20.5 |
S129 | 0.20 | 16.0 |
S130 | 0.19 | 16.4 |
S131 | 0.24 | 16.6 |
S132 | 0.18 | 16.1 |
S134 | 0.15 | 18.0 |
S135 | 0.14 | 18.2 |
S137 | 0.19 | 15.3 |
S138 | 0.18 | 15.8 |
Shift % | Un-transfected cell | Human CNTN4 transfected cell |
Second antibody only | 0.81 | 1.25 |
A13WB2 | 7.74 | 86.6 |
A13WB4 | 1.13 | 84.7 |
A13WB7 | 5.47 | 86.4 |
A13WB24 | 1.6 | 85.1 |
A13WB25 | 0.65 | 82.4 |
A13WB73 | 0.72 | 86.4 |
A13SF1 | 0.52 | 83.8 |
A13SF2 | 4.24 | 83.5 |
A13SF7 | 0.42 | 83.2 |
A13SF8 | 17.6 | 90.4 |
A13SF16 | 6.23 | 84.8 |
A13SF19 | 0.77 | 79.6 |
A13SF20 | 0.42 | 82.2 |
A13SF21 | 0.36 | 80.4 |
A13SF74 | 1.11 | 84.1 |
A35WB1 | 3.93 | 83.9 |
A35WB27 | 9.39 | 88.2 |
A35SF3 | 0.75 | 81.9 |
A35SF5 | 0.39 | 82.6 |
A35SF8 | 0.55 | 80.4 |
A35SF13 | 1.59 | 82.1 |
A35SF14 | 0.58 | 81.6 |
A35SF37 | 5.96 | 86.6 |
A35SF38 | 0.72 | 77.9 |
A35SF39 | 3.87 | 80 |
A35SF75 | 0.39 | 84.8 |
A35SF90 | 0.49 | 82.8 |
EC50, nM | Human CNTN4 | Mouse CNTN4 |
A-01 | 0.011 | 0.011 |
항원 | 해리 상수 Kd |
인간 CNTN-4 단백질 | 3.365 X 10-8 M |
서열번호 | 영역 | 서열 |
서열번호 18 | VLA | ALTQPSSVSANLGETVKITCSGSSGSYGWYQQKSPGSAPVTLIYDNTNRPSDIPSRFSGSGSGSTGTLTITGVRAEDEAVYYCGGYDGSTDVFGAGTTLTVL |
서열번호 2 | VHA | AVTLDESEGGLQTPGGALSLVCKASGFTFSSFNMFWVRQAPGKGLEYVAEISGGGGSTWYAPAVKGRATISRDNGQSTVRLQLNNLRAEDTGTYYCAKSADTWSYGAATIDAWGHGTEVIVSS |
서열번호 156 | VL1 | ELTQDPAVSVALGQTVRITCSGSSGSYGWYQQKPGQAPVLVIYDNTNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCGGYDGSTDVFGGGTKLTVL |
서열번호 157 | VH1 | EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFNMFWVRQAPGKGLEWVSEISGGGGSTWYAPAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKSADTWSYGAATIDAWGQGTLVTVSS |
서열번호 158 | VL2 | ELTQDPAVSVALGQTVRITCSGSSGSYGWYQQKPGQAPVTLIYDNTNRPSGIPDRFSGSSSGSTGSLTITGAQAEDEADYYCGGYDGSTDVFGGGTKLTVL |
서열번호 159 | VH2 | EVQLLESEGGLVQPGGSLRLSCAASGFTFSSFNMFWVRQAPGKGLEWVAEISGGGGSTWYAPAVKGRATISRDNSKNTVYLQMNSLRAEDTAVYYCAKSADTWSYGAATIDAWGQGTLVTVSS |
EC50, nM | Human CNTN4 | Mouse CNTN4 |
A-01 | 0.011 | 0.011 |
LAH2 | 0.017 | 0.017 |
L1H2 | 0.028 | 0.029 |
L2H2 | 0.018 | 0.019 |
항원 | 해리 상수 Kd |
인간 CNTN-4 단백질 | 9.319 X 10-8 M |
Claims (28)
- 서열번호 70의 아미노산 서열을 포함하는 경쇄 CDR1;서열번호 88의 아미노산 서열을 포함하는 경쇄 CDR2;서열번호 116의 아미노산 서열을 포함하는 경쇄 CDR3;서열번호 58의 아미노산 서열을 포함하는 중쇄 CDR1;서열번호 89의 아미노산 서열을 포함하는 중쇄 CDR2; 및서열번호 115의 아미노산 서열을 포함하는 중쇄 CDR3;을 포함하는, 항-CNTN4 항체 또는 그의 항원 결합 단편.
- 서열번호 18의 아미노산 서열을 포함하는 경쇄 가변 영역; 및서열번호 2의 아미노산 서열을 포함하는 중쇄 가변 영역을 포함하는, 항-CNTN4 항체 또는 그의 항원 결합 단편.
- 서열번호 156의 아미노산 서열을 포함하는 경쇄 가변 영역; 및서열번호 159의 아미노산 서열을 포함하는 중쇄 가변 영역을 포함하는, 항-CNTN4 항체 또는 그의 항원 결합 단편.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 인간 또는 마우스 CNTN4 단백질에 특이적으로 결합하는 것인, 항-CNTN4 항체 또는 그의 항원 결합 단편.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 1 X 10-7 M 이하의 해리 상수 (Kd)로 인간 CNTN4 단백질에 결합하는 것인, 항-CNTN4 항체 또는 그의 항원 결합 단편.
- 제1항 내지 제3항 중 어느 한 항에 있어서, T 세포 활성을 증가시키는 것인, 항-CNTN4 항체 또는 그의 항원 결합 단편.
- 제6항에 있어서, 상기 T 세포는 CD4+ T 세포 또는 CD8+ T 세포인 것인, 항-CNTN4 항체 또는 그의 항원 결합 단편.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 상기 항원 결합 단편이 Fab, Fab', Fab'-SH, Fv, 단일 쇄 항체 scFv, (Fab')2 단편, 단일 도메인 항체, 디아바디 (dAb), 및 선형 항체로 이루어지는 군으로부터 선택되는 것인, 항-CNTN4 항체 또는 그의 항원 결합 단편.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 상기 항체는 키메라 항체 또는 인간화 항체인 것인, 항-CNTN4 항체 또는 그의 항원 결합 단편.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 상기 항체는 다중 특이적 항체인 것인, 항-CNTN4 항체 또는 그의 항원 결합 단편.
- 제1항 내지 제3항 중 어느 한 항에 있어서, 상기 항체는 약물과 컨쥬게이션된 형태인 것인, 항-CNTN4 항체 또는 그의 항원 결합 단편.
- 제1항 내지 제3항 중 어느 한 항의 항체 또는 그의 항원 결합 단편을 암호화하는 핵산 분자.
- 제12항의 핵산 분자를 포함하는 재조합 발현 벡터.
- 제1항 내지 제3항 중 어느 한 항의 항-CNTN4 항체 또는 그의 항원 결합 단편을 포함하는, 암의 예방 또는 치료용 약학 조성물.
- 제14항에 있어서, 상기 암은 CNTN4를 발현하는 암인 것인, 암의 예방 또는 치료용 약학 조성물.
- 제1항 내지 제3항 중 어느 한 항의 항-CNTN4 항체 또는 그의 항원 결합 단편; 및 추가 항암제를 포함하는, 암의 예방 또는 치료용 약학 조성물.
- 제16항에 있어서, 상기 추가 항암제는 면역 관문 억제제 또는 화학요법제인 것인, 암의 예방 또는 치료용 약학 조성물.
- 제17항에 있어서, 상기 면역 관문 억제제는 항-CTLA-4 항체, 항-PD-1 항체, 및 항-PD-L1 항체로 이루어진 군으로부터 선택되는 하나 이상인 것인, 암의 예방 또는 치료용 약학 조성물.
- 제16항에 있어서, 항-CNTN4 항체 또는 그의 항원 결합 단편; 및 추가 항암제는 하나의 제제로 동시에 투여되거나, 또는 별개의 제제로 동시에 또는 순차적으로 투여되는 것인, 암의 예방 또는 치료용 약학 조성물.
- 제1항 내지 제3항 중 어느 한 항의 항-CNTN4 항체 또는 그의 항원 결합 단편을 포함하며, 추가 항암요법과 함께 사용되는 것인, 암의 예방 또는 치료용 약학 조성물.
- 제20항에 있어서, 상기 추가 항암요법은 면역 관문 억제제, 화학요법제 및 방사선 치료요법으로 이루어지는 군으로부터 선택되는 하나 이상인 것인, 암의 예방 또는 치료용 약학 조성물.
- 암의 예방 또는 치료를 위한 제1항 내지 제3항 중 어느 한 항의 항-CNTN4 항체 또는 그의 항원 결합 단편의 용도.
- 암의 예방 또는 치료용 약제를 제조하기 위한 제1항 내지 제3항 중 어느 한 항의 항-CNTN4 항체 또는 그의 항원 결합 단편의 용도.
- 제1항 내지 제3항 중 어느 한 항의 유효량의 항-CNTN4 항체 또는 그의 항원 결합 단편을 대상체에 투여하는 단계를 포함하는 암의 예방 또는 치료 방법.
- 제1항 내지 제3항 중 어느 한 항의 유효량의 항-CNTN4 항체 또는 그의 항원 결합 단편; 및 유효량의 추가 항암제를 대상체에 투여하는 단계를 포함하는 암의 예방 또는 치료 방법.
- 제25항에 있어서, 상기 추가 항암제는 면역 관문 억제제 또는 화학요법제인 것인, 방법.
- 제26항에 있어서, 상기 면역 관문 억제제는 항-CTLA-4 항체, 항-PD-1 항체, 및 항-PD-L1 항체로 이루어진 군으로부터 선택되는 하나 이상인 것인, 방법.
- 제25항에 있어서, 유효량의 항-CNTN4 항체 또는 그의 항원 결합 단편; 및 유효량의 추가 항암제는 하나의 제제로 동시에 대상체에 투여되거나, 또는 별개의 제제로 동시에 또는 순차적으로 대상체에 투여되는 것인, 방법.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023561099A JP2024514109A (ja) | 2021-04-06 | 2022-04-05 | 抗cntn4抗体及びその使用 |
EP22784923.9A EP4321535A1 (en) | 2021-04-06 | 2022-04-05 | Anti-cntn4 antibody and use thereof |
CN202280026442.6A CN117157324A (zh) | 2021-04-06 | 2022-04-05 | 抗cntn4抗体及其用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0044840 | 2021-04-06 | ||
KR1020210044840A KR102291725B1 (ko) | 2021-04-06 | 2021-04-06 | 항-cntn4 항체 및 그의 용도 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022216014A1 true WO2022216014A1 (ko) | 2022-10-13 |
Family
ID=77499186
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/004890 WO2022216014A1 (ko) | 2021-04-06 | 2022-04-05 | 항-cntn4 항체 및 그의 용도 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP4321535A1 (ko) |
JP (1) | JP2024514109A (ko) |
KR (1) | KR102291725B1 (ko) |
CN (1) | CN117157324A (ko) |
WO (1) | WO2022216014A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102291725B1 (ko) * | 2021-04-06 | 2021-08-23 | 주식회사 지놈앤컴퍼니 | 항-cntn4 항체 및 그의 용도 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017086367A1 (ja) * | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法 |
KR20190116930A (ko) * | 2018-04-05 | 2019-10-15 | 주식회사 지놈앤컴퍼니 | 항암 및 면역증강용 신규 타겟 |
KR20190129739A (ko) * | 2018-05-11 | 2019-11-20 | 광주과학기술원 | 락토코커스 락티스 gen3033 균주, 및 이를 포함하는 암의 예방 또는 치료용 조성물 |
KR102291725B1 (ko) * | 2021-04-06 | 2021-08-23 | 주식회사 지놈앤컴퍼니 | 항-cntn4 항체 및 그의 용도 |
-
2021
- 2021-04-06 KR KR1020210044840A patent/KR102291725B1/ko active IP Right Grant
-
2022
- 2022-04-05 JP JP2023561099A patent/JP2024514109A/ja active Pending
- 2022-04-05 WO PCT/KR2022/004890 patent/WO2022216014A1/ko active Application Filing
- 2022-04-05 CN CN202280026442.6A patent/CN117157324A/zh active Pending
- 2022-04-05 EP EP22784923.9A patent/EP4321535A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017086367A1 (ja) * | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法 |
KR20190116930A (ko) * | 2018-04-05 | 2019-10-15 | 주식회사 지놈앤컴퍼니 | 항암 및 면역증강용 신규 타겟 |
KR20190129739A (ko) * | 2018-05-11 | 2019-11-20 | 광주과학기술원 | 락토코커스 락티스 gen3033 균주, 및 이를 포함하는 암의 예방 또는 치료용 조성물 |
KR102291725B1 (ko) * | 2021-04-06 | 2021-08-23 | 주식회사 지놈앤컴퍼니 | 항-cntn4 항체 및 그의 용도 |
Non-Patent Citations (2)
Title |
---|
CHA MI YOUNG, HOUH YOUN KYUNG, KIM YUN YEON, KIM HYUNUK, CHUNG JOO-YEON, PARK KYUNG MI, PARK HANSOO: "Abstract 688: Anti-CNTN4 antibody, GENA-104A07 suppresses tumor growth in murine syngeneic tumor models by regulating T cell function", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 81, no. 13_Supplement, 1 July 2021 (2021-07-01), 2019 San Antonio Breast Cancer Symposium, San Antonio, Texas , pages 688 - 688, XP055976186, ISSN: 0008-5472, DOI: 10.1158/1538-7445.AM2021-688 * |
LUCIE EVENEPOEL, ET AL.: "Expression of Contactin 4 Is Associated With Malignant Behavior in Pheochromocytomas and Paragangliomas", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 103, no. 1, 1 January 2018 (2018-01-01), US , pages 46 - 55, XP055642749, ISSN: 0021-972X, DOI: 10.1210/jc.2017-01314 * |
Also Published As
Publication number | Publication date |
---|---|
JP2024514109A (ja) | 2024-03-28 |
EP4321535A1 (en) | 2024-02-14 |
CN117157324A (zh) | 2023-12-01 |
KR102291725B1 (ko) | 2021-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019229076B2 (en) | Anti-TIGIT antibodies and uses thereof | |
WO2020111913A1 (en) | Anti-4-1bb antibody and use thereof | |
WO2019098682A1 (ko) | 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체 | |
WO2014119969A1 (ko) | 보체 관련 질환의 예방 및 치료를 위한 c5 항체 및 방법 | |
WO2021006619A1 (ko) | B7-h3에 특이적으로 결합하는 항체 및 그의 용도 | |
WO2021133036A1 (ko) | 항-lilrb1 항체 및 그의 용도 | |
WO2019132533A1 (ko) | 항-pd-l1 항체 및 이의 용도 | |
WO2022216014A1 (ko) | 항-cntn4 항체 및 그의 용도 | |
WO2018174629A1 (en) | Anti-ceacam1 antibody and use thereof | |
WO2022231032A1 (ko) | 항-cntn4 특이적 항체 및 그의 용도 | |
WO2017074013A1 (ko) | 인간 및 마우스 sema3a에 교차결합하는 항체 및 그의 용도 | |
WO2019216675A1 (ko) | 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체 | |
WO2022131889A1 (ko) | Taci 단백질의 용도 | |
WO2022025585A1 (ko) | 항-lilrb1 항체 및 그의 용도 | |
WO2022177392A1 (ko) | Cd47에 대한 단일 도메인 항체 및 이의 용도 | |
WO2016084993A1 (ko) | 신규 EGFRvIII 항체 및 이를 포함하는 조성물 | |
WO2021235697A1 (ko) | Cd22에 특이적인 항체 및 이의 용도 | |
WO2022244908A1 (ko) | 항-bcam 항체 또는 그의 항원 결합 단편 | |
WO2019151632A1 (ko) | 중동호흡기증후군 코로나바이러스에 중화활성을 갖는 결합 분자 | |
WO2017142294A1 (ko) | EGFRvIII에 대한 항체 및 이의 용도 | |
WO2021118246A1 (en) | Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof | |
WO2023224390A1 (ko) | Ccr7의 활성 조절 항체 | |
WO2022131687A2 (ko) | 항-hvem 항체, 및 이와 관련된 조성물 및 방법 | |
WO2022124764A1 (ko) | Cd47에 특이적인 항체 및 이의 용도 | |
WO2021132746A1 (en) | Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22784923 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18285459 Country of ref document: US Ref document number: 2023561099 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022784923 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022784923 Country of ref document: EP Effective date: 20231106 |